PBYI - Puma Biotechnology Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Select Current Price & Safety Score Price: 11.02 USD StockBonds Safety Grade: A Altman Z-Score (Bankruptcy Risk): -0.61 StockBond Score: 2.77 Company Description Puma Biotechnology Inc is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care Its lead drug candidate orally administered neratinib PB272 targets a range of indications These include patients with earlystage HER2overexpressedamplified breast cancer as well as adults suffering from advanced or metastatic HER2positive breast cancer when used in combination with capecitabine Furthermore PB272 is being explored for solid tumors exhibiting HER2 mutations The company holds a licensing agreement with Pfizer Inc for this drug and has established sublicensing partnerships with Specialised Therapeutics Asia Pte Ltd CANbridge BIOMED Limited Pint Pharma International SA Knight Therapeutics Inc Pierre Fabre Medicament SAS and Bixink Therapeutics Co Ltd Established in 2010 Puma Biotechnology maintains its headquarters in Los Angeles California